Plegridy (PEG-interferon β-1a) / Biogen 
Welcome,         Profile    Billing    Logout  

7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Plegridy (PEG-interferon β-1a) / Biogen
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
04/30
09/30
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
07/24
05/27
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Not yet recruiting
N/A
100
Europe
Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs)
Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V.
Multiple Sclerosis (MS)
03/26
03/26
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31

Download Options